Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Flagship Pioneering

Flagship Pioneering

U.S-based venture capital firm funding U.S-startups in the life science industry.

Established in 2000, Flagship Pioneering (previously known as Flagship Ventures) is a venture capital firm founded by Noubar Afeyan and Edwin Kania. The firm primarily operates from Cambridge, Massachusetts although it also has an office in Ann Arbor, Michigan. The firm is currently managing a portfolio containing 37 companies and has sold off its shares in 121 companies. The firm’s most recent investment occurred in December 2018 for Indigo Agriculture, a biotechnology company specializing in plant microbiome agricultural services.

Funding

Flagship Pioneering focuses on funding startups that operate in the United States, especially in the Midwest region. The firm prefers to fund companies in the therapeutics, health technologies, life science, sustainability and clean technology business industries. It provides financing for companies at various stages of development, from incubation to growth stage. With its latest funding round raised in September 2017, the firm has managed to collect a total fund of $2.8 billion. During the September 2017 funding round, the firm amassed a total of $618 million in capital.

Timeline

May 10, 2021
Flagship Pioneering announces the launch of its newest company, Laronde, which aims to pioneer new eRNA-based medication, a new type of drug developed at Flagship Labs by general partner Avak Kahvejian.
May 27, 2020
Flagship Pioneering launches new agtech company to manage insect populations.

Funding Rounds

Invested in

Associated Investment Funds

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Conor Hale
September 9, 2021
FierceBiotech
After landing a job at the life sciences incubator Flagship Pioneering earlier this summer, former FDA Commissioner Stephen Hahn will now serve a stint as the interim medical chief at one of the venture firm's portfolio companies, focused on blood collection and COVID-19 diagnostics.
FinSMEs
August 30, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Alex Keown
June 15, 2021
BioSpace
The new division would benefit from Hahn's experience and help steer the company's Preemptive Medicine and Health Security initiative.
BioSpace
June 15, 2021
BioSpace
Tessera Therapeutics announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors.
Kyle LaHucik
June 14, 2021
FierceBiotech
Ex-FDA Commissioner Stephen Hahn, M.D., is joining Moderna incubator Flagship Pioneering six months after granting the company an emergency use authorization for its COVID-19 vaccine.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.